<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0002986" disease_type="Disease or Syndrome" abbrv="">Fabry disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e>, OMIM 301500) is a rare <z:hpo ids='HP_0001417'>X-linked</z:hpo> lysosomal storage disorder of the glycosphigolipid metabolism caused by total or partial deficiency of the lysosomal enzyme alpha-galactosidase A (α-<z:chebi fb="125" ids="28260">gal</z:chebi> A) </plain></SENT>
<SENT sid="1" pm="."><plain>Progressive intralysosomal accumulation of neutral <z:chebi fb="0" ids="24402">glycosphingolipids</z:chebi> in a variety of cell types triggers a cascade of pathophysiological events including cellular <z:hpo ids='HP_0011420'>death</z:hpo>, compromised energy metabolism, small vessel injury, K(Ca)3.1 channel dysfunction in endothelial cells, <z:mp ids='MP_0003674'>oxidative stress</z:mp>, impaired autophagosome maturation, tissue <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and, importantly, development of irreversible cardiac and renal tissue <z:mp ids='MP_0003045'>fibrosis</z:mp>, leading to major multisystemic manifestations </plain></SENT>
<SENT sid="2" pm="."><plain>Cardiovascular complications of the disease are very frequent and contribute substantially to disease-related morbidity and mortality in men </plain></SENT>
<SENT sid="3" pm="."><plain>Cardiovascular involvement is the leading cause of premature <z:hpo ids='HP_0011420'>death</z:hpo> in heterozygous female patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001712'>Left ventricular hypertrophy</z:hpo> is the most prominent cardiac manifestation followed by conduction system disease, valve dysfunction, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, vessel disease and coronary microvascular dysfunction </plain></SENT>
<SENT sid="5" pm="."><plain>The diagnosis of subclinical forms of the disease, before the development of <z:mp ids='MP_0001625'>cardiac hypertrophy</z:mp>, using newer techniques (tissue doppler imaging, strain rate and cardiac magnetic resonance) is crucial to the early initation of the treatment </plain></SENT>
<SENT sid="6" pm="."><plain>Greatest benefit of the enzyme replacement treatment is achieved when started at an early stage of the disease before extensive <z:mp ids='MP_0003045'>fibrosis</z:mp> or other irreversible tissue damage takes place </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0002986" disease_type="Disease or Syndrome" abbrv="">Fabry disease</z:e> should be concluded in the differential diagnosis algorithm of idiopathic <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Determination of Alpha-<z:chebi fb="125" ids="28260">Gal</z:chebi> A activity on plasma and peripheral leukocytes in males and genetic testing in females are the diagnostic gold-standards.   </plain></SENT>
</text></document>